Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
NCT ID: NCT01211639
Last Updated: 2015-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
24 participants
OBSERVATIONAL
2010-10-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetics of Familial and Sporadic ALS
NCT00821132
Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome
NCT00342602
GWAS in NMDAR Encephalitis
NCT05225883
Study of Inherited Neurological Disorders
NCT00004568
Protective Genetic Factors Against Neurological Diseases
NCT03914599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Central Neurology Associates
Cullman, Alabama, United States
Rocky Mountain MS Center at Anschutz Medical Campus University Colorado Denver
Aurora, Colorado, United States
Rush Medical Center - Rush Multiple Sclerosis Center
Chicago, Illinois, United States
St. Vincent Hospital, St. Vincent Neuroscience Institute
Indianapolis, Indiana, United States
Central Neurology
Hastings, Nebraska, United States
Clinical Research Center UH, The Nebraska Medical Center
Omaha, Nebraska, United States
NYU Hospital for Joint Disease, MS Care Center
New York, New York, United States
University of Rochester
Rochester, New York, United States
Research Site
Cincinnati, Ohio, United States
Neurology of Bend, LLC
Bend, Oregon, United States
Research Site
Würzburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
101JC403
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.